Citigroup Maintains Buy on Madrigal Pharmaceuticals, Lowers Price Target to $382
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst David Lebovitz maintains a Buy rating on Madrigal Pharmaceuticals (MDGL) but lowers the price target from $389 to $382.

May 08, 2024 | 7:16 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Citigroup maintains a Buy rating on Madrigal Pharmaceuticals but lowers the price target from $389 to $382.
The adjustment in price target by Citigroup, while maintaining a Buy rating, suggests a continued positive outlook on MDGL but with slightly tempered expectations. This could lead to a neutral short-term impact on the stock as the market digests the minor adjustment in valuation expectations.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100